CO6670526A2 - Anticuerpos peptídicos beta amiloide anti-n3p glu y usos de los mismos - Google Patents

Anticuerpos peptídicos beta amiloide anti-n3p glu y usos de los mismos

Info

Publication number
CO6670526A2
CO6670526A2 CO13028596A CO13028596A CO6670526A2 CO 6670526 A2 CO6670526 A2 CO 6670526A2 CO 13028596 A CO13028596 A CO 13028596A CO 13028596 A CO13028596 A CO 13028596A CO 6670526 A2 CO6670526 A2 CO 6670526A2
Authority
CO
Colombia
Prior art keywords
beta amyloid
peptide antibodies
glu peptide
amyloid anti
antibodies
Prior art date
Application number
CO13028596A
Other languages
English (en)
Inventor
Jirong Lu
Ying Tang
Ronald Bradley Damattos
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO6670526A2 publication Critical patent/CO6670526A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Abstract

La presente invención se refiere a anticuerpos Aß anti-N3pGlu o fragmento de unión al antígeno de los mismos.Además, la presente invención proporciona el uso de los anticuerpos Aß anti-N3pGlu o fragmento de unión al antígeno de los mismos para el tratamiento de la enfermedad de Alzheimer.
CO13028596A 2010-08-12 2013-02-12 Anticuerpos peptídicos beta amiloide anti-n3p glu y usos de los mismos CO6670526A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37302610P 2010-08-12 2010-08-12

Publications (1)

Publication Number Publication Date
CO6670526A2 true CO6670526A2 (es) 2013-05-15

Family

ID=44543826

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13028596A CO6670526A2 (es) 2010-08-12 2013-02-12 Anticuerpos peptídicos beta amiloide anti-n3p glu y usos de los mismos

Country Status (38)

Country Link
US (2) US8679498B2 (es)
EP (3) EP2603523B1 (es)
JP (2) JP5980207B2 (es)
KR (1) KR101498833B1 (es)
CN (2) CN103068848B (es)
AU (1) AU2011289629B2 (es)
BR (1) BR112013004056B8 (es)
CA (1) CA2805114C (es)
CL (1) CL2013000390A1 (es)
CO (1) CO6670526A2 (es)
CR (1) CR20130016A (es)
CY (2) CY1120144T1 (es)
DK (3) DK3042917T3 (es)
DO (1) DOP2013000029A (es)
EA (1) EA023021B1 (es)
EC (1) ECSP13012436A (es)
ES (3) ES2664128T3 (es)
GT (1) GT201300036A (es)
HK (1) HK1180703A1 (es)
HR (3) HRP20160151T1 (es)
HU (2) HUE037524T2 (es)
IL (2) IL224030B (es)
LT (2) LT3042917T (es)
MA (1) MA34461B1 (es)
ME (3) ME03661B (es)
MX (2) MX342782B (es)
MY (2) MY181969A (es)
NO (1) NO3042917T3 (es)
NZ (2) NZ626665A (es)
PE (1) PE20130817A1 (es)
PL (3) PL3339323T3 (es)
PT (2) PT3339323T (es)
RS (3) RS57026B1 (es)
SG (2) SG187586A1 (es)
SI (3) SI3339323T1 (es)
UA (1) UA107600C2 (es)
WO (1) WO2012021469A1 (es)
ZA (1) ZA201300437B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
PL3339323T3 (pl) * 2010-08-12 2020-05-18 Eli Lilly And Company Przeciwciała przeciwko peptydowi N3pGlu amyloidu beta i ich zastosowania
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
EP3102611A4 (en) * 2014-02-03 2017-08-23 Cangene Corporation Humanized beta-amyloid binding molecules and uses thereof
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
AU2015287227B2 (en) 2014-07-10 2021-02-18 Universitat Zurich Immune-stimulating monoclonal antibodies against human interleukin-2
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
US20170363645A1 (en) 2014-12-19 2017-12-21 Probiodrug Ag Novel Method for the Detection of pGlu-Abeta Peptides
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
CN106699888B (zh) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
MD3353212T2 (ro) * 2015-09-23 2022-03-31 Regeneron Pharma Anticorpi bispecifici anti-CD3 optimizați și utilizările acestora
CN108473569B (zh) 2016-01-11 2022-11-22 苏黎世大学 针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TW201740944A (zh) * 2016-03-15 2017-12-01 美國禮來大藥廠 組合療法
TW201740954A (zh) * 2016-03-16 2017-12-01 美國禮來大藥廠 組合療法
TWI735600B (zh) * 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
EP3496750A2 (en) * 2016-08-09 2019-06-19 Eli Lilly and Company Combination therapy
EP3500296A1 (en) * 2016-08-18 2019-06-26 Eli Lilly and Company Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody
AR110470A1 (es) * 2016-10-21 2019-04-03 Lilly Co Eli Terapia de combinación para tratar la enfermedad de alzheimer
WO2018078038A1 (en) 2016-10-28 2018-05-03 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
EP3532053A1 (en) 2016-10-28 2019-09-04 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
TW201827467A (zh) * 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
EA202090555A1 (ru) 2017-08-22 2020-06-08 Байоджен Ма Инк. Фармацевтические композиции, содержащие антитела к бета-амилоиду
HUE057202T2 (hu) 2017-12-14 2022-04-28 H Lundbeck As Kombinációs kezelések 1H-pirazolo[4,3-b]piridinek alkalmazásával
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
CR20210492A (es) 2019-03-26 2021-11-19 Janssen Pharmaceutica Nv ANTICUERPOS CONTRA AMILOIDES-ß CON PIROGLUTAMATO Y USOS DE ESTOS
MX2022004311A (es) 2019-10-15 2022-05-10 Lilly Co Eli Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante.
WO2021257808A2 (en) * 2020-06-17 2021-12-23 Proviva Therapeutics (Hong Kong) Limited Antibodies to fibroblast activation protein and b7h3
JP2023535024A (ja) 2020-07-23 2023-08-15 オター プロシーナ リミテッド 抗ａベータ抗体
PE20231507A1 (es) * 2020-10-02 2023-09-26 Lilly Co Eli Metodos para reducir el contenido de proteinas de la celula huesped en procesos de purificacion de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteinas de la celula huesped
TW202243690A (zh) 2021-01-11 2022-11-16 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2023070064A1 (en) 2021-10-22 2023-04-27 Eli Lilly And Company O-glcnacase (oga) inhibitor combination therapy
WO2023076971A1 (en) 2021-10-29 2023-05-04 Eli Lilly Company Compounds and methods targeting interleukin-34
JP2023067832A (ja) 2021-10-29 2023-05-16 イーライ リリー アンド カンパニー インターロイキン－３４を標的とする化合物及び方法
TW202334210A (zh) 2021-10-29 2023-09-01 美商美國禮來大藥廠 靶向介白素-34之化合物及方法
WO2023076970A1 (en) 2021-10-29 2023-05-04 Eli Lilly And Company Compounds and methods targeting interleukin-34
WO2023150483A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease
WO2024020470A1 (en) 2022-07-21 2024-01-25 Eli Lilly And Company PHARMACEUTICAL SOLUTIONS OF ANTI-N3pGlu Aβ ANTIBODIES AND USES THEREOF

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
AU2003250102B2 (en) 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2005018424A2 (en) * 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
PL1720909T3 (pl) * 2004-02-23 2012-04-30 Lilly Co Eli Przeciwciało anty-abeta
MX2007000998A (es) * 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
AR062065A1 (es) 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
BRPI0810118A8 (pt) * 2007-04-18 2015-09-29 Janssen Alzheimer Immunotherap Método para tratar doença, método para efetuar profilaxia contra caa, uso de um agente, método para reduzir amilóide vascular em um paciente, e, kit para tratamento
MX2010013647A (es) 2008-06-12 2011-04-05 Affiris Ag Compuestos para tratar sintomas asociados con la enfermedad de parkinson.
EP2321348A2 (en) 2008-07-09 2011-05-18 University of Zürich Method of promoting neurogenesis
WO2010009987A2 (en) * 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
US8795664B2 (en) 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
PL3339323T3 (pl) * 2010-08-12 2020-05-18 Eli Lilly And Company Przeciwciała przeciwko peptydowi N3pGlu amyloidu beta i ich zastosowania

Also Published As

Publication number Publication date
CA2805114C (en) 2017-12-05
EA023021B1 (ru) 2016-04-29
BR112013004056B8 (pt) 2022-10-18
MY163521A (en) 2017-09-15
ME02352B (me) 2016-06-20
PL3042917T3 (pl) 2018-07-31
ZA201300437B (en) 2014-06-25
AU2011289629A1 (en) 2013-02-14
RS54685B1 (en) 2016-08-31
US20140065138A1 (en) 2014-03-06
CN103068848B (zh) 2015-11-25
MX2013001716A (es) 2013-10-28
EP3339323B1 (en) 2019-11-13
HUE037524T2 (hu) 2018-09-28
NZ626665A (en) 2016-04-29
CR20130016A (es) 2013-03-21
EP2603523A1 (en) 2013-06-19
HRP20160151T1 (hr) 2016-03-11
NO3042917T3 (es) 2018-07-21
JP2013536191A (ja) 2013-09-19
MX342782B (es) 2016-10-12
EP2603523B1 (en) 2016-01-27
DOP2013000029A (es) 2013-03-15
US8961972B2 (en) 2015-02-24
PE20130817A1 (es) 2013-07-18
IL285226B2 (en) 2023-02-01
PL3339323T3 (pl) 2020-05-18
SI2603523T1 (sl) 2016-04-29
ES2664128T3 (es) 2018-04-18
CA2805114A1 (en) 2012-02-16
AU2011289629B2 (en) 2014-07-03
ECSP13012436A (es) 2013-03-28
BR112013004056A2 (pt) 2020-08-04
ME03032B (me) 2018-10-20
CY1122458T1 (el) 2021-01-27
CL2013000390A1 (es) 2014-03-21
EA201270813A1 (ru) 2013-05-30
LT3339323T (lt) 2020-02-10
NZ606095A (en) 2014-11-28
SI3042917T1 (en) 2018-04-30
EP3042917B1 (en) 2018-02-21
BR112013004056B1 (pt) 2022-05-17
HRP20192233T1 (hr) 2020-03-06
US8679498B2 (en) 2014-03-25
KR101498833B1 (ko) 2015-03-04
SG187586A1 (en) 2013-03-28
IL224030B (en) 2022-04-01
HRP20180616T1 (hr) 2018-07-13
ME03661B (me) 2020-07-20
CN105111308A (zh) 2015-12-02
PL2603523T3 (pl) 2016-07-29
DK3339323T3 (da) 2020-01-20
JP2016179985A (ja) 2016-10-13
ES2564252T3 (es) 2016-03-21
SI3339323T1 (sl) 2019-12-31
LT3042917T (lt) 2018-05-10
KR20130051989A (ko) 2013-05-21
MA34461B1 (fr) 2013-08-01
MY181969A (en) 2021-01-15
DK3042917T3 (en) 2018-04-23
IL285226A (en) 2021-09-30
PT3339323T (pt) 2020-01-14
CY1120144T1 (el) 2018-12-12
ES2764728T3 (es) 2020-06-04
HK1180703A1 (zh) 2013-10-25
JP6395755B2 (ja) 2018-09-26
SG10201509330XA (en) 2015-12-30
DK2603523T3 (en) 2016-03-21
HUE028678T2 (en) 2016-12-28
RS59652B1 (sr) 2020-01-31
CN105111308B (zh) 2019-03-12
JP5980207B2 (ja) 2016-08-31
EP3042917A1 (en) 2016-07-13
EP3339323A1 (en) 2018-06-27
UA107600C2 (uk) 2015-01-26
US20130142806A1 (en) 2013-06-06
IL285226B (en) 2022-10-01
WO2012021469A1 (en) 2012-02-16
MX355268B (es) 2018-04-11
CN103068848A (zh) 2013-04-24
GT201300036A (es) 2014-07-16
PT3042917T (pt) 2018-05-02
RS57026B1 (sr) 2018-05-31

Similar Documents

Publication Publication Date Title
CO6670526A2 (es) Anticuerpos peptídicos beta amiloide anti-n3p glu y usos de los mismos
CY1121392T1 (el) Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης
CY1122987T1 (el) Αντισωματα εναντι αμυλοειδους βητα
CO2017012974A2 (es) Anticuerpos de unión a tau
CR20190445A (es) ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
CO7250445A2 (es) Proteínas de unión a antígeno st2
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
CY1116842T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CL2012001817A1 (es) Anticuerpo monoclonal que reconoce epitope conformacional y se une a peptidos amiloides solubles polimericos y peptidos amiloides oligomericos, particularmente a los peptidos abeta amiloides solubles polimericos y peptidos abeta amiloides oligomericos; polinucleotidos que codifican dicho anticuerpo; composicion terapeutica que comprende el anticuerpo; uso del anticuerpo para tratar enfermedades y trastornos causados o asociados a las proteinas amiloides (div. sol. 1742-2008).
CL2014002750A1 (es) Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer
BR112013021562A2 (pt) anticorpos para cd70
CO2017012971A2 (es) Anticuerpos de unión a tau
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
ECSP11011445A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b
AR090923A1 (es) Anticuerpos anti-il-23
DOP2012000232A (es) Proteínas de unión a antigeno especificas para el componente amiloide serico p
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
AR124605A2 (es) Anticuerpos anti-il-36r
AR118080A2 (es) Proteínas de unión a antígeno dirigidas contra el receptor
CY1117265T1 (el) Αντισωματα aνti-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
TN2013000045A1 (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
CR11498A (es) Metodos para el tratamiento de la obesidad y enfermedades y desordenes relacionados a la obesidad
TH133365A (th) แอนติ-N3pGlu อะมัยลอยด์ เบต้าเพปไทด์ แอนติบอดี และการใช้ของมัน
CL2013001231A1 (es) Anticuerpo anti il-23p19 o su fragmento de union a antigeno; polinucleotido que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar diversas enfermedades.